New share issue round about to close on Sunday 17 February

Tomorrow, Lipum will close a share issue raising SEK 25 million in addition to support from Horizon 2020 of SEK 23 million grant. 

The capital will finance the preclinical work and the development of a production method up to the start of toxicology studies next year.

See the full interview (in swedish) from BioStock with our CEO Einar Pontén where he also talks about the plans for a market listing in 2020 and the interest from venture capital companies.

Dr Einar Pontén
CEO
+46 (0)70-578 34 95
Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.

Tags:

About Us

Lipum aims for better quality of life for the millions suffering from chronic inflammatory diseases, including children. Distressed by pain, disability, and comorbidities many have to leave a normal working life in advance. We intend to increase their quality of life and decrease the considerable health care and societal costs.

Subscribe